AZ&Me™ Prescription Savings Program for People with Medicare Part D Removes Out-of-Pocket Spend Requirement

  AZ&Me™ Prescription Savings Program for People with Medicare Part D Removes
  Out-of-Pocket Spend Requirement

Business Wire

WILMINGTON, Del. -- November 15, 2012

AstraZeneca (NYSE:AZN)today announced that it is simplifying the enrollment
process for the AZ&Me™ Prescription Savings Program for people with Medicare
Part D by removing an out-of-pocket spend requirement.

As of Jan. 1, the program will no longer require that people with Medicare
prescription drug coverage spend 3 percent of their annual household income on
out-of-pocket costs for prescription medicines within the calendar year to
qualify.

Those who meet all of the other program eligibility requirements may begin
receiving their AstraZeneca medicines for free upon successfully completing
the enrollment process. To be eligible for the program, a Medicare beneficiary
must:

  *Be enrolled in Medicare Part D.
  *Have an annual household income at or below $35,000 for individuals or
    $48,000 for couples.
  *Not be enrolled in the Medicare Limited Income Subsidy.

"We regularly evaluate how we can simplify our program enrollment process and
saw an opportunity to do so for people with Medicare prescription drug
coverage," said Jennifer McGovern, Director, AZ&Me Prescription Savings
Programs. "Removing the out-of-pocket spend requirement means that people will
no longer have to gather documentation from their pharmacy before completing
their enrollment, saving them time and helping them get their AstraZeneca
medicines sooner."

AstraZeneca has offered prescription savings programs for 34 years and offers
one of the industry’s most generous programs. The company will continue to
make program enhancements that better serve patients and the advocates who
help them.

"Prescription assistance programs help fill an important need for many people
who have Medicare Part D coverage, but may not be able to access all of their
medicines because of limited financial resources," said Nora Dowd Eisenhower,
senior vice president for economic security and director of the Center for
Benefits Access, National Council on Aging. "We salute AstraZeneca for its
continued leadership in patient assistance and will use this opportunity to
remind Medicare beneficiaries, caregivers and advocates that these kinds of
programs are a helpful resource for many who don’t qualify for extra help
through the Medicare Limited Income Subsidy."

For a list of medicines covered under Medicare Part D, visit
http://www.astrazeneca-us.com/medicines/help-affording-your-medicines/list-of-covered-medicines.

                                   - ENDS -

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a
primary focus on the discovery, development and commercialization of
prescription medicines for gastrointestinal, cardiovascular, neuroscience,
respiratory and inflammation, oncology and infectious disease. AstraZeneca
operates in over 100 countries and its innovative medicines are used by
millions of patients worldwide.

For more information about AstraZeneca in the U.S. or our AZ&Me™ Prescription
Savings programs, please visit: www.astrazeneca-us.comor call 1-800-AZandMe
(292-6363).

Contact:

AstraZeneca
Media Inquiries:
Lynn Shepherd, 302-885-8911